Activities of daily living · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Quality of life, · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Cognitive function · People with MCI/prodromal AD
1 finding from 1 review
Combined cognitive‐functional outcome · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Any adverse events · Apathy in people with mild‐to‐moderate Alzheimer's disease
Souvenaid showed no clear difference in any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Memory (specific cognitive function) · People with MCI/prodromal AD
1 finding from 1 review
Executive function (specific cognitive function) · People with MCI/prodromal AD
1 finding from 1 review
Functional outcomes · People with MCI/prodromal AD
1 finding from 1 review
Combined cognitive‐functional outcome · People with MCI/prodromal AD
1 finding from 1 review
Any adverse event · People with MCI/prodromal AD
Souvenaid showed no clear difference in any adverse event compared with placebo (moderate certainty).
1 finding from 1 review
Cognitive function · People with mild Alzheimer's disease
1 finding from 1 review
Memory (specific cognitive function) · People with mild Alzheimer's disease
1 finding from 1 review
Length of delirium episode · end‐of‐life patients with advanced cancer and an episode of agitated delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of delirium · end‐of‐life patients with advanced cancer and an episode of agitated delirium
1 finding from 1 review
Any adverse event · end‐of‐life patients with advanced cancer and an episode of agitated delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · end‐of‐life patients with advanced cancer and an episode of agitated delirium
1 finding from 1 review
Mortality from all causes · end‐of‐life patients with advanced cancer and an episode of agitated delirium
Benzodiazepines (lorazepam) showed no clear difference in mortality from all causes compared with placebo (low certainty).
1 finding from 1 review
Cognitive function · people with Alzheimer's disease
2 findings from 1 review
Cognitive function · people with severe Alzheimer's disease
2 findings from 1 review
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher clinician‐rated global impression tests (improved compared with… compared with placebo (moderate certainty).
1 finding from 1 review